Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

FDA Public Meeting Report on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications".

Akbar M, Berry-Bibee E, Blithe DL, Day RS, Edelman A, Höchel J, Jamshidi R, Kim MJ, Li L, Purohit VS, Turpin JA, Scott PE, Strauss DG, Sun H, Tepper NK, Zhang L, Yu C.

J Clin Pharmacol. 2018 Dec;58(12):1655-1665. doi: 10.1002/jcph.1285. Epub 2018 Aug 24.

PMID:
30144093
2.

Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges.

Turpin JA.

Drug Deliv Transl Res. 2011 Jun;1(3):194-200. doi: 10.1007/s13346-011-0034-2. Epub 2011 May 21.

3.

Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals.

Young JM, Turpin JA, Musib R, Sharma OK.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):737-43. doi: 10.1089/AID.2010.0313. Epub 2011 Jan 15.

4.
5.

Topical microbicides: a promising approach for controlling the AIDS pandemic via retroviral zinc finger inhibitors.

Turpin JA, Schito ML, Jenkins LM, Inman JK, Appella E.

Adv Pharmacol. 2008;56:229-56. Review. No abstract available.

PMID:
18086414
6.

Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeys.

Schito ML, Soloff AC, Slovitz D, Trichel A, Inman JK, Appella E, Turpin JA, Barratt-Boyes SM.

Curr HIV Res. 2006 Jul;4(3):379-86.

PMID:
16842089
7.

In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.

Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, Buckheit RW Jr, Watson K, Dezzutti CS, Cummins JE, Bromley E, Richardson-Harman N, Pallansch LA, Lackman-Smith C, Osterling C, Mankowski M, Miller SR, Catalone BJ, Welsh PA, Howett MK, Wigdahl B, Turpin JA, Reichelderfer P.

Antimicrob Agents Chemother. 2006 Feb;50(2):713-23.

8.

Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.

Dong HF, Wigmore K, Carrington MN, Dean M, Turpin JA, Howard OM.

Genes Immun. 2005 Oct;6(7):609-19.

9.

Potent inhibition of HIV-1 entry by (s4dU)35.

Horváth A, Tokés S, Hartman T, Watson K, Turpin JA, Buckheit RW Jr, Sebestyén Z, Szöllosi J, Benko I, Bardos TJ, Dunn JA, Fésüs L, Tóth FD, Aradi J.

Virology. 2005 Apr 10;334(2):214-23.

10.

Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.

Mori T, O'Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW Jr, McMahon JB, Boyd MR.

J Biol Chem. 2005 Mar 11;280(10):9345-53. Epub 2004 Dec 21.

11.

Optimization of unique, uncharged thioesters as inhibitors of HIV replication.

Srivastava P, Schito M, Fattah RJ, Hara T, Hartman T, Buckheit RW Jr, Turpin JA, Inman JK, Appella E.

Bioorg Med Chem. 2004 Dec 15;12(24):6437-50.

PMID:
15556761
12.

The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.

Turpin JA.

Expert Rev Anti Infect Ther. 2003 Jun;1(1):97-128. Review.

PMID:
15482105
13.

Functional redundancy of the human CCL4 and CCL4L1 chemokine genes.

Howard OM, Turpin JA, Goldman R, Modi WS.

Biochem Biophys Res Commun. 2004 Jul 30;320(3):927-31.

PMID:
15240137
14.

Antiviral activity of hop constituents against a series of DNA and RNA viruses.

Buckwold VE, Wilson RJ, Nalca A, Beer BB, Voss TG, Turpin JA, Buckheit RW 3rd, Wei J, Wenzel-Mathers M, Walton EM, Smith RJ, Pallansch M, Ward P, Wells J, Chuvala L, Sloane S, Paulman R, Russell J, Hartman T, Ptak R.

Antiviral Res. 2004 Jan;61(1):57-62.

PMID:
14670594
15.

Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1.

Chen X, Yang L, Zhang N, Turpin JA, Buckheit RW, Osterling C, Oppenheim JJ, Howard OM.

Antimicrob Agents Chemother. 2003 Sep;47(9):2810-6.

16.

Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin.

O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR.

Antimicrob Agents Chemother. 2003 Aug;47(8):2518-25.

17.

In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model.

Schito ML, Goel A, Song Y, Inman JK, Fattah RJ, Rice WG, Turpin JA, Sher A, Appella E.

AIDS Res Hum Retroviruses. 2003 Feb;19(2):91-101.

PMID:
12639244
18.

Metal-dependent inhibition of HIV-1 integrase.

Neamati N, Lin Z, Karki RG, Orr A, Cowansage K, Strumberg D, Pais GC, Voigt JH, Nicklaus MC, Winslow HE, Zhao H, Turpin JA, Yi J, Skalka AM, Burke TR Jr, Pommier Y.

J Med Chem. 2002 Dec 19;45(26):5661-70.

PMID:
12477350
19.

Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts.

Mori T, Barrientos LG, Han Z, Gronenborn AM, Turpin JA, Boyd MR.

Protein Expr Purif. 2002 Oct;26(1):42-9.

PMID:
12356469
20.

Psychologic and physiologic effects of dieting in adolescents.

Daee A, Robinson P, Lawson M, Turpin JA, Gregory B, Tobias JD.

South Med J. 2002 Sep;95(9):1032-41. Review.

PMID:
12356104
21.

Considerations and development of topical microbicides to inhibit the sexual transmission of HIV.

Turpin JA.

Expert Opin Investig Drugs. 2002 Aug;11(8):1077-97. Review.

PMID:
12150703
22.

Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents.

Xu G, Kannan A, Hartman TL, Wargo H, Watson K, Turpin JA, Buckheit RW Jr, Johnson AA, Pommier Y, Cushman M.

Bioorg Med Chem. 2002 Aug;10(8):2807-16.

PMID:
12057671
23.

Synthesis and biological properties of amino acid amide ligand-based pyridinioalkanoyl thioesters as anti-HIV agents.

Song Y, Goel A, Basrur V, Roberts PE, Mikovits JA, Inman JK, Turpin JA, Rice WG, Appella E.

Bioorg Med Chem. 2002 May;10(5):1263-73.

PMID:
11886789
24.

Benzamide-based thiolcarbamates: a new class of HIV-1 NCp7 inhibitors.

Goel A, Mazur SJ, Fattah RJ, Hartman TL, Turpin JA, Huang M, Rice WG, Appella E, Inman JK.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):767-70.

PMID:
11858998
25.

Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.

Xu G, Hartman TL, Wargo H, Turpin JA, Buckheit RW, Cushman M.

Bioorg Med Chem. 2002 Feb;10(2):283-90.

PMID:
11741777
26.

The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.

Xu G, Micklatcher M, Silvestri MA, Hartman TL, Burrier J, Osterling MC, Wargo H, Turpin JA, Buckheit RW Jr, Cushman M.

J Med Chem. 2001 Nov 22;44(24):4092-113.

PMID:
11708913
27.

Synthesis and anti-HIV activity of cosalane analogues incorporating two dichlorodisalicylmethane pharmacophore fragments.

Casimiro-Garcia A, De Clercq E, Pannecouque C, Witvrouw M, Loftus TL, Turpin JA, Buckheit RW Jr, Fanwick PE, Cushman M.

Bioorg Med Chem. 2001 Nov;9(11):2827-41.

PMID:
11597463
28.

Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors.

Xu G, Loftus TL, Wargo H, Turpin JA, Buckheit RW Jr, Cushman M.

J Org Chem. 2001 Sep 7;66(18):5958-64.

PMID:
11529718
29.

The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactions.

Saavedra JE, Srinivasan A, Bonifant CL, Chu J, Shanklin AP, Flippen-Anderson JL, Rice WG, Turpin JA, Davies KM, Keefer LK.

J Org Chem. 2001 May 4;66(9):3090-8.

PMID:
11325274
30.

Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores.

Santhosh KC, Paul GC, De Clercq E, Pannecouque C, Witvrouw M, Loftus TL, Turpin JA, Buckheit RW Jr, Cushman M.

J Med Chem. 2001 Mar 1;44(5):703-14.

PMID:
11262081
31.

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.

Buckheit RW Jr, Watson K, Fliakas-Boltz V, Russell J, Loftus TL, Osterling MC, Turpin JA, Pallansch LA, White EL, Lee JW, Lee SH, Oh JW, Kwon HS, Chung SG, Cho EH.

Antimicrob Agents Chemother. 2001 Feb;45(2):393-400.

32.

Anti-HIV activity of a series of cosalane amino acid conjugates.

Santhosh KC, De Clercq E, Pannecouque C, Witvrouw M, Loftus TL, Turpin JA, Buckheit RW, Cushman M.

Bioorg Med Chem Lett. 2000 Nov 20;10(22):2505-8.

PMID:
11086716
33.

Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates.

Paul GC, De Clercq E, Pannecouque C, Witvrouw M, Loftus TL, Turpin JA, Buckheit RW Jr, Cushman M.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2149-52.

PMID:
10999491
34.

Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain.

Casimiro-Garcia A, De Clercq E, Pannecouque C, Witvrouw M, Stup TL, Turpin JA, Buckheit RW Jr, Cushman M.

Bioorg Med Chem. 2000 Jan;8(1):191-200.

PMID:
10968278
35.

Inactivation of HIV-1 nucleocapsid protein P7 by pyridinioalkanoyl thioesters. Characterization of reaction products and proposed mechanism of action.

Basrur V, Song Y, Mazur SJ, Higashimoto Y, Turpin JA, Rice WG, Inman JK, Appella E.

J Biol Chem. 2000 May 19;275(20):14890-7.

36.

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group.

Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, Gormley GJ, Pearlman DS.

Ann Intern Med. 2000 Jan 18;132(2):97-104.

PMID:
10644288
37.

Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.

Casimiro-Garcia A, Micklatcher M, Turpin JA, Stup TL, Watson K, Buckheit RW, Cushman M.

J Med Chem. 1999 Nov 18;42(23):4861-74.

PMID:
10579849
38.

Thiazolothiazepine inhibitors of HIV-1 integrase.

Neamati N, Turpin JA, Winslow HE, Christensen JL, Williamson K, Orr A, Rice WG, Pommier Y, Garofalo A, Brizzi A, Campiani G, Fiorini I, Nacci V.

J Med Chem. 1999 Aug 26;42(17):3334-41.

PMID:
10464020
39.

Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function.

Howard OM, Shirakawa AK, Turpin JA, Maynard A, Tobin GJ, Carrington M, Oppenheim JJ, Dean M.

J Biol Chem. 1999 Jun 4;274(23):16228-34.

40.

Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency.

Cushman M, Insaf S, Paul G, Ruell JA, De Clercq E, Schols D, Pannecouque C, Witvrouw M, Schaeffer CA, Turpin JA, Williamson K, Rice WG.

J Med Chem. 1999 May 20;42(10):1767-77.

PMID:
10346929
41.

Chicoric acid analogues as HIV-1 integrase inhibitors.

Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin JA, Aberham C, Strebel K, Kohn K, Witvrouw M, Pannecouque C, Debyser Z, De Clercq E, Rice WG, Pommier Y, Burke TR Jr.

J Med Chem. 1999 Apr 22;42(8):1401-14.

PMID:
10212126
42.

Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers.

Turpin JA, Song Y, Inman JK, Huang M, Wallqvist A, Maynard A, Covell DG, Rice WG, Appella E.

J Med Chem. 1999 Jan 14;42(1):67-86.

PMID:
9888834
43.

Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function.

Howard OM, Korte T, Tarasova NI, Grimm M, Turpin JA, Rice WG, Michejda CJ, Blumenthal R, Oppenheim JJ.

J Leukoc Biol. 1998 Jul;64(1):6-13. Review.

PMID:
9665268
44.

Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application.

Howard OM, Oppenheim JJ, Hollingshead MG, Covey JM, Bigelow J, McCormack JJ, Buckheit RW Jr, Clanton DJ, Turpin JA, Rice WG.

J Med Chem. 1998 Jun 18;41(13):2184-93.

PMID:
9632350
45.

Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins.

Huang M, Maynard A, Turpin JA, Graham L, Janini GM, Covell DG, Rice WG.

J Med Chem. 1998 Apr 23;41(9):1371-81.

PMID:
9554870
46.

Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription.

Turpin JA, Buckheit RW Jr, Derse D, Hollingshead M, Williamson K, Palamone C, Osterling MC, Hill SA, Graham L, Schaeffer CA, Bu M, Huang M, Cholody WM, Michejda CJ, Rice WG.

Antimicrob Agents Chemother. 1998 Mar;42(3):487-94.

47.

Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication.

Gong W, Howard OM, Turpin JA, Grimm MC, Ueda H, Gray PW, Raport CJ, Oppenheim JJ, Wang JM.

J Biol Chem. 1998 Feb 20;273(8):4289-92.

48.

Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.

McDonnell NB, De Guzman RN, Rice WG, Turpin JA, Summers MF.

J Med Chem. 1997 Jun 20;40(13):1969-76.

PMID:
9207937
49.

Differential infection of CD34+ cell-derived dendritic cells and monocytes with lymphocyte-tropic and monocyte-tropic HIV-1 strains.

Warren MK, Rose WL, Cone JL, Rice WG, Turpin JA.

J Immunol. 1997 May 15;158(10):5035-42.

PMID:
9144524
50.

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

Rice WG, Turpin JA, Huang M, Clanton D, Buckheit RW Jr, Covell DG, Wallqvist A, McDonnell NB, DeGuzman RN, Summers MF, Zalkow L, Bader JP, Haugwitz RD, Sausville EA.

Nat Med. 1997 Mar;3(3):341-5.

PMID:
9055865

Supplemental Content

Loading ...
Support Center